AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
53 hedge funds and large institutions have $5.67M invested in AEON Biopharma Inc in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
2% more funds holding
Funds holding: 52 → 53 (+1)
20% less capital invested
Capital invested by funds: $7.07M → $5.67M (-$1.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$15.2K |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
+$11.1K |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
+$7.61K |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$3.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
Fir Tree Capital Management
New York
|
-$24K |
| 2 |
AR
Advisory Research
Chicago,
Illinois
|
-$8K |
| 3 |
CC
Centiva Capital
New York
|
-$4K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.03K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$239 |
AEON.WS Hedge Fund Activity: Q3 2022 in Review
53 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q3 2022, worth a combined $5.67M — down 20% from $7.07M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AEON.WS positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Periscope Capital, adding an estimated $15.2K. The largest seller was Fir Tree Capital Management, exiting entirely with an estimated $24K sold.
- 53 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q3 2022, up from 52 in Q2 2022.
- Funds reported $5.67M of AEON Biopharma Inc stock for Q3 2022, down 20% quarter-over-quarter.
- 4 funds opened new AEON Biopharma Inc positions in Q3 2022 and 3 closed out, a net change of +1 holder.
- The largest AEON Biopharma Inc buyer in Q3 2022 was Periscope Capital, an estimated $15.2K added.
- The largest AEON Biopharma Inc seller in Q3 2022 was Fir Tree Capital Management, an estimated $24K sold.
Based on aggregated 13F filings for Q3 2022.